PL3362470T3 - Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny - Google Patents

Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny

Info

Publication number: PL3362470T3
Authority: PL; Poland
Prior art keywords: chlorotoxin; domain; chimeric antigen; antigen receptors; receptors containing
Prior art date: 2015-10-13

Application number

PL16791158T

Other languages

English (en)

Inventor

Michael BARISH

Christine E. BROWN

Stephen J. Forman

Dongrui WANG

Original Assignee

City Of Hope

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-13

Filing date

2016-10-13

Publication date

2022-02-21

2016-10-13 Application filed by City Of Hope filed Critical City Of Hope

2022-02-21 Publication of PL3362470T3 publication Critical patent/PL3362470T3/pl

Links

108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
101710164760 Chlorotoxin Proteins 0.000 title 1
QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 title 1
229960005534 chlorotoxin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/405—Invertebrates antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Insects & Arthropods (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL16791158T 2015-10-13 2016-10-13 Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny PL3362470T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562241021P	2015-10-13	2015-10-13
PCT/US2016/056901 WO2017066481A1 (en)	2015-10-13	2016-10-13	Chimeric antigen receptors containing a chlorotoxin domain
EP16791158.5A EP3362470B1 (en)	2015-10-13	2016-10-13	Chimeric antigen receptors containing a chlorotoxin domain

Publications (1)

Publication Number	Publication Date
PL3362470T3 true PL3362470T3 (pl)	2022-02-21

Family

ID=57233854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16791158T PL3362470T3 (pl)	2015-10-13	2016-10-13	Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny

Country Status (12)

Country	Link
US (2)	US11230577B2 (pl)
EP (2)	EP3362470B1 (pl)
JP (3)	JP7085990B2 (pl)
KR (1)	KR20180056780A (pl)
CN (1)	CN108368159A (pl)
CA (1)	CA3001833A1 (pl)
DK (1)	DK3362470T3 (pl)
ES (1)	ES2902987T3 (pl)
IL (2)	IL302560B2 (pl)
PL (1)	PL3362470T3 (pl)
PT (1)	PT3362470T (pl)
WO (1)	WO2017066481A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017136829A1 (en)	2016-02-05	2017-08-10	City Of Hope	Administration of engineered t cells for treatment of cancers in the central nervous system
AU2017355504C1 (en)	2016-11-04	2024-06-20	2Seventy Bio, Inc.	Anti-BCMA CAR T cell compositions
KR20250072712A (ko)	2016-12-02	2025-05-26	앤젤레스 테라퓨틱스, 인코포레이티드	합성 면역 수용체 및 이의 사용 방법
KR20240005979A (ko) *	2016-12-09	2024-01-12	유에이비 리서치 파운데이션	키메라성 클로로톡신 수용체
WO2019084018A1 (en) *	2017-10-23	2019-05-02	City Of Hope	CAR FOR THE TREATMENT OF HIV INFECTION
JP2020103673A (ja) *	2018-12-28	2020-07-09	株式会社三洋物産	遊技機
JP2020103677A (ja) *	2018-12-28	2020-07-09	株式会社三洋物産	遊技機
JP2020103675A (ja) *	2018-12-28	2020-07-09	株式会社三洋物産	遊技機
JP2020108445A (ja) *	2018-12-28	2020-07-16	株式会社三洋物産	遊技機
JP2020103674A (ja) *	2018-12-28	2020-07-09	株式会社三洋物産	遊技機
JP2020108441A (ja) *	2018-12-28	2020-07-16	株式会社三洋物産	遊技機
JP2020108442A (ja) *	2018-12-28	2020-07-16	株式会社三洋物産	遊技機
JP2020108444A (ja) *	2018-12-28	2020-07-16	株式会社三洋物産	遊技機
JP2020108446A (ja) *	2018-12-28	2020-07-16	株式会社三洋物産	遊技機
JP2020108443A (ja) *	2018-12-28	2020-07-16	株式会社三洋物産	遊技機
JP2020103676A (ja) *	2018-12-28	2020-07-09	株式会社三洋物産	遊技機
US20220195060A1 (en) *	2019-04-05	2022-06-23	2Seventy Bio, Inc.	Manufacturing anti-bcma car t cells
JP2022533247A (ja) *	2019-05-24	2022-07-21	シティ・オブ・ホープ	Ｃｃｒ４陽性悪性腫瘍治療用ｃｃｒ４標的化キメラ抗原受容体修飾ｔ細胞
US20230374085A1 (en) *	2020-03-11	2023-11-23	City Of Hope	Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
JP7714161B2 (ja)	2020-12-30	2025-07-29	ヴェーエルゲーミニプロテインザルトコルユエンムュコドョーレシュヴェントヴァルシャサーク	クロロトキシン誘導体およびその使用
EP4281087A4 (en) *	2021-01-20	2025-03-19	IN8bio, Inc.	MULTIVALENT CHIMERIC CHLOROTOXIN ANTIGEN RECEPTORS
CN117242090A (zh)	2021-03-30	2023-12-15	希望之城公司	CAR T细胞疗法和IFNγ
US20230190799A1 (en) *	2021-07-21	2023-06-22	City Of Hope	Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
WO2023092733A1 (zh) *	2021-11-25	2023-06-01	苏州慧疗生物医药科技有限公司	一种用于有效递送核酸的环状多肽载体及其变化形式
CN114014941B (zh) *	2022-01-10	2022-04-12	卡瑞济(北京)生命科技有限公司	靶向IL13Rα2的嵌合抗原受体及其用途
US20250144139A1 (en) *	2022-02-11	2025-05-08	Fred Hutchinson Cancer Center	Chimeric antigen receptors binding steap1
CA3258273A1 (en) *	2022-06-14	2023-12-21	Purdue Research Foundation	Neutrophils derived from pluripotent stem cells expressing carbapenems loaded with drug nanoparticles and their uses
WO2025235801A1 (en)	2024-05-08	2025-11-13	City Of Hope	Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005232616A1 (en) *	2004-04-06	2005-10-27	Transmolecular, Inc.	Diagnosis and treatment of myeloid and lymphoid cell cancers
CN100564517C (zh)	2006-09-21	2009-12-02	武汉大学	一种蝎抗神经胶质瘤肽及其制备方法和应用
PL3006459T3 (pl) *	2008-08-26	2022-01-17	City Of Hope	Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
EP2491116A4 (en) *	2009-10-22	2013-12-11	Univ Jefferson	CELL-BASED ANTI-CANCER COMPOSITIONS AND METHODS OF MAKING AND USING SAME
WO2011097533A1 (en)	2010-02-04	2011-08-11	Transmolecular, Inc.	Chlorotoxin polypeptides and conjugates and uses thereof
CA2913029A1 (en) *	2012-12-10	2014-06-19	Fred Hutchinson Cancer Research Center	Lipocalin fusion partners
TWI654206B (zh)	2013-03-16	2019-03-21	諾華公司	使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10144770B2 (en) *	2013-10-17	2018-12-04	National University Of Singapore	Chimeric receptors and uses thereof in immune therapy
CN113307880B (zh)	2014-01-13	2025-07-04	希望之城公司	在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
EP3280437A4 (en) *	2015-04-06	2018-09-12	Jianhua Yu	Egfr-directed car therapy for glioblastoma
KR101888387B1 (ko) *	2015-05-29	2018-08-20	코닌클리케 필립스 엔.브이.	리브들을 포함하는 밀봉 개스킷을 갖는 블렌더

2016
- 2016-10-13 ES ES16791158T patent/ES2902987T3/es active Active
- 2016-10-13 IL IL302560A patent/IL302560B2/en unknown
- 2016-10-13 WO PCT/US2016/056901 patent/WO2017066481A1/en not_active Ceased
- 2016-10-13 IL IL258670A patent/IL258670B2/en unknown
- 2016-10-13 PL PL16791158T patent/PL3362470T3/pl unknown
- 2016-10-13 DK DK16791158.5T patent/DK3362470T3/da active
- 2016-10-13 CA CA3001833A patent/CA3001833A1/en active Pending
- 2016-10-13 PT PT167911585T patent/PT3362470T/pt unknown
- 2016-10-13 US US15/767,960 patent/US11230577B2/en active Active
- 2016-10-13 EP EP16791158.5A patent/EP3362470B1/en active Active
- 2016-10-13 KR KR1020187013153A patent/KR20180056780A/ko active Pending
- 2016-10-13 EP EP21197997.6A patent/EP3985027A1/en active Pending
- 2016-10-13 JP JP2018519030A patent/JP7085990B2/ja active Active
- 2016-10-13 CN CN201680072823.2A patent/CN108368159A/zh active Pending
2021
- 2021-11-05 US US17/520,402 patent/US20220177528A1/en active Pending
2022
- 2022-01-20 JP JP2022007016A patent/JP7331162B2/ja active Active
2023
- 2023-08-09 JP JP2023129665A patent/JP7674425B2/ja active Active

Also Published As

Publication number	Publication date
JP2023144018A (ja)	2023-10-06
JP7085990B2 (ja)	2022-06-17
CN108368159A (zh)	2018-08-03
JP7674425B2 (ja)	2025-05-09
US20220177528A1 (en)	2022-06-09
DK3362470T3 (da)	2021-12-13
EP3362470A1 (en)	2018-08-22
KR20180056780A (ko)	2018-05-29
IL258670A (en)	2018-06-28
IL258670B2 (en)	2023-10-01
JP2018531015A (ja)	2018-10-25
CA3001833A1 (en)	2017-04-20
PT3362470T (pt)	2021-12-10
US20190389917A1 (en)	2019-12-26
ES2902987T3 (es)	2022-03-30
EP3985027A1 (en)	2022-04-20
US11230577B2 (en)	2022-01-25
IL302560A (en)	2023-07-01
IL302560B2 (en)	2025-08-01
JP7331162B2 (ja)	2023-08-22
IL258670B1 (en)	2023-06-01
EP3362470B1 (en)	2021-09-22
JP2022060226A (ja)	2022-04-14
WO2017066481A1 (en)	2017-04-20
WO2017066481A8 (en)	2017-11-23
IL302560B1 (en)	2025-04-01

Publication	Publication Date	Title
PL3362470T3 (pl)	2022-02-21	Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny
IL263220A (en)	2018-12-31	Cd33 specific chimeric antigen receptors
IL272227A (en)	2020-03-31	Anti-tigit antibodies
IL269405A (en)	2019-11-28	Anti-sirp alpha antibodies
IL251030B (en)	2021-07-29	Chimeric antigen receptors
DK3625259T3 (da)	2024-07-08	Anti-sirpalpha-antistoffer
EP3661558A4 (en)	2021-08-11	ANTI-IL1RAP ANTIBODIES
HUE060019T2 (hu)	2023-01-28	Anti-LAG3 antitestek
EP3569709A4 (en)	2020-08-19	ANTI-GPC3 ANTIBODIES
IL265219A (en)	2019-05-30	Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
HUE056074T2 (hu)	2022-01-28	BCMA kiméra antigénreceptorok
PL3274366T3 (pl)	2020-06-15	Chimeryczny receptor antygenowy
DK3411404T3 (da)	2023-01-30	Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner
IL251963A0 (en)	2017-06-29	Anti-pd-1 antibodies
DK3294764T3 (da)	2021-01-25	Kimæriske antigenreceptor sammensætninger
HUE041976T2 (hu)	2019-06-28	Cisztein-módosított ellenanyagokat tartalmazó konjugált vegyületek
EP3691447A4 (en)	2021-08-11	ANTI-TRANSTHYRETINE ANTIBODY
DK3406634T3 (da)	2024-07-08	Antistoffer omfattende kimæriske, konstante domæner
DK3606961T3 (da)	2022-07-04	Garp-tgf-beta-antistoffer
EP3604344A4 (en)	2021-01-06	CHEMICAL ANTIGENIC RECEPTOR
EP3507369C0 (en)	2024-06-12	ANTI-CD20 ANTIBODIES
DK3484921T3 (da)	2022-02-07	Anti-IL-22R antistoffer
DK3452515T3 (da)	2025-11-17	Her-2-bindende antistoffer
HUE054148T2 (hu)	2021-08-30	Anti-ORAI1 antitest
IL266950A (en)	2019-07-31	Chimeric chlorotoxin receptors